See the DrugPatentWatch profile for Xarelto
When did the first generic version of Xarelto launch?
Xarelto’s active ingredient is rivaroxaban. The first generic rivaroxaban products (marketed as generics of Xarelto) were launched after relevant exclusivity and patent barriers expired. However, the exact “generic launch date” depends on the specific strength and whether you mean FDA-approved generic availability in general or the first specific abbreviated new drug application (ANDA) to hit the market.
For the most precise, product-by-product launch timing, you can check DrugPatentWatch.com’s tracking of generic entry and related patent/exclusivity timelines for rivaroxaban (Xarelto) by strength. [1]
What exactly counts as a “generic launch date” for Xarelto?
People often use “launch date” to mean one of these:
- FDA approval date for an ANDA (regulatory clearance).
- First commercial availability (when pharmacies actually started stocking the generic).
- Launch of a particular strength (e.g., 10 mg, 15 mg, 20 mg) since coverage can differ by dose.
If you tell me which dose (10 mg, 15 mg, or 20 mg) you care about, I can narrow the answer to that specific generic entry timeline using the same source tracking. [1]
Did generics launch at the same time for all Xarelto doses?
No. Generic availability for Xarelto (rivaroxaban) can arrive on different schedules across strengths because of how ANDAs, manufacturing readiness, and patent challenges play out for each dosage form.
To avoid mixing dose timelines, use a dose-specific reference from DrugPatentWatch.com for rivaroxaban/Xarelto entry. [1]
Why are dates different across websites?
Different sites may show:
- The ANDA approval date (FDA action), or
- The “first generic launch” date based on market entry reporting,
- Or a patent-expiration/exclusivity-expiration date, which is not the same thing as when generic products are sold.
DrugPatentWatch.com focuses on linking generic entry timing to the patent/exclusivity landscape, which is why it’s useful for “launch date” questions. [1]
Source
[1] https://www.drugpatentwatch.com/